Fisetin ( DrugBank: Fisetin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05593588 (ClinicalTrials.gov) | March 1, 2023 | 21/10/2022 | Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency | Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID) | Common Variable Immunodeficiency;Interstitial Lung Disease Due to Systemic Disease | Drug: Fisetin;Drug: Placebo | Avni Joshi | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |